CA2284132C — Blister package and packaged tablet
Assigned to Cima Labs Inc · Expires 2004-09-07 · 22y expired
What this patent protects
The invention is a blister package (10) for containing frangible dosage forms {26) while protecting the dosage forms from damage during transport and opening of the package. A blister sheet (13) defines at least one recess (22) in which a flangible dosage form is disposed and a p…
USPTO Abstract
The invention is a blister package (10) for containing frangible dosage forms {26) while protecting the dosage forms from damage during transport and opening of the package. A blister sheet (13) defines at least one recess (22) in which a flangible dosage form is disposed and a pellable sheet of lidding material (12) overlies the recesses (22) to cover the dosage form therein. Each dosage form engages its recess to prevent shifting of the dosage form during transport. Indicia (42) on the blister package (10) directs the user with regard to the procedure for opening the package without damaging the dosage form. Unsealed areas (23) in the package, which provide a portion of lidding material which the user can grasp to peel open the package, are provided with intersections defining dimples (39) which hide the graspable portion of lidding material from children.
Drugs covered by this patent
- Remodulin (TREPROSTINIL) · United Therap
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.